1. Home
  2. ACRV vs HYB Comparison

ACRV vs HYB Comparison

Compare ACRV & HYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • HYB
  • Stock Information
  • Founded
  • ACRV 2018
  • HYB 1987
  • Country
  • ACRV United States
  • HYB United States
  • Employees
  • ACRV N/A
  • HYB N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • HYB Investment Managers
  • Sector
  • ACRV Health Care
  • HYB Finance
  • Exchange
  • ACRV Nasdaq
  • HYB Nasdaq
  • Market Cap
  • ACRV 225.8M
  • HYB 193.3M
  • IPO Year
  • ACRV 2022
  • HYB 1999
  • Fundamental
  • Price
  • ACRV $7.87
  • HYB $8.23
  • Analyst Decision
  • ACRV Strong Buy
  • HYB
  • Analyst Count
  • ACRV 5
  • HYB 0
  • Target Price
  • ACRV $22.60
  • HYB N/A
  • AVG Volume (30 Days)
  • ACRV 103.0K
  • HYB 39.6K
  • Earning Date
  • ACRV 11-07-2024
  • HYB 01-01-0001
  • Dividend Yield
  • ACRV N/A
  • HYB 6.67%
  • EPS Growth
  • ACRV N/A
  • HYB N/A
  • EPS
  • ACRV N/A
  • HYB N/A
  • Revenue
  • ACRV N/A
  • HYB N/A
  • Revenue This Year
  • ACRV N/A
  • HYB N/A
  • Revenue Next Year
  • ACRV N/A
  • HYB N/A
  • P/E Ratio
  • ACRV N/A
  • HYB N/A
  • Revenue Growth
  • ACRV N/A
  • HYB N/A
  • 52 Week Low
  • ACRV $3.19
  • HYB $6.23
  • 52 Week High
  • ACRV $11.90
  • HYB $7.41
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 57.76
  • HYB 47.19
  • Support Level
  • ACRV $6.87
  • HYB $8.24
  • Resistance Level
  • ACRV $8.16
  • HYB $8.35
  • Average True Range (ATR)
  • ACRV 0.33
  • HYB 0.08
  • MACD
  • ACRV 0.13
  • HYB -0.02
  • Stochastic Oscillator
  • ACRV 77.86
  • HYB 31.58

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About HYB New America High Income Fund Inc. (The)

New America High Income Fund Inc is a diversified, closed‐end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.

Share on Social Networks: